🚨Trade Alert 🚨 OKYO

With a $5.50 Price Target, OKYO is a Growing Eye Care Company to Keep Your Eye On…. ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ With a $5.50 Price Target, OKYO is a Growing Eye Care Company to Keep Your Eye On…. Greetings Investors, There is a lot of discussion on which sectors of the market are safer than others. Some insist on technology, others insist on precious metals, but most would agree that healthcare is a relatively safe place to park in. And when you consider categories of health that are not talked about enough, the growth potential is staggering. Savvy investors may want to give some serious consideration to publicly traded eye care companies, including OKYO Pharma Limited (NASDAQ: OKYO). This growing biotech company is developing first-in-class pharmaceutical therapies to treat inflammatory eye diseases. [www.okyopharma.com](~/AASl5QA~/RgRm3YPFP0RlaHR0cDovL3d3dy5va3lvcGhhcm1hLmNvbT9fa3g9Xy1IU3BvMnk5bERXSmU1Zks2eDM2V2NwZU1iMEV6c1pmSXZmU1N2dEFMdDd5cDVfbzM3d05vSU16TlQwbDJEWC5UYTlyaExXA3NwY0IKZPnF_vpk77XKIVIbdHJpc3RyYW1iYWxkd2luODhAZ21haWwuY29tWAQABeGx) Shares of OKYO have been on a rampage in recent weeks, more than doubling from around $1.20 to over $3 a share recently! The stock also currently has a “BUY” rating at [BarChart.com](~/AASl5QA~/RgRm3YPFP0SAaHR0cHM6Ly93d3cuYmFyY2hhcnQuY29tL3N0b2Nrcy9xdW90ZXMvT0tZTy9vdmVydmlldz9fa3g9Xy1IU3BvMnk5bERXSmU1Zks2eDM2V2NwZU1iMEV6c1pmSXZmU1N2dEFMdDd5cDVfbzM3d05vSU16TlQwbDJEWC5UYTlyaExXA3NwY0IKZPnF_vpk77XKIVIbdHJpc3RyYW1iYWxkd2luODhAZ21haWwuY29tWAQABeGx). OKYO may finally be getting proper Wall Street recognition as it addresses a significant unmet need in a multi-billion-dollar market: Dry eye disease, or DED. If you have dry eye disease, you know just how uncomfortable it is. Dry eye is notorious for itchiness, burning, and general discomfort. This can make your eyes feel uncomfortable or extremely painful. And for contact lens wearers, it can make putting them in almost impossible. Dry eye disease can also cause light sensitivity which compounds the pain even more. What’s even more scary is that it could truly become serious to the point of ultimately causing vision loss! According to Fortune Business Insights, global [Dry Eye Syndrome Market](~/AASl5QA~/RgRm3YPFP4QlAWh0dHBzOi8vd3d3Lmdsb2JlbmV3c3dpcmUuY29tL1RyYWNrZXI_ZGF0YT0wRGhwZzJSYkp0elNENW15WjJ5UWFWdU15dXd6bkxmX2J3WkhpNmJlR0dMakxLN3VQQTcxakRLelN0T1Z6UTNJZ0NMWXFvSURINVM5Ym1ZTkh4OGZZSy1Ockh1TVRuU2Y2ZnQ5NC1RMDZSc2hZcFZlQ2tyeTlSOExuaHRzS0NUVkxaYTJocGNyVFdIa2NaS1NsQi1vSzRtbnFMemoyeXFIZ05YRzZDTmlEUE0lM0QmX2t4PV8tSFNwbzJ5OWxEV0plNWZLNngzNldjcGVNYjBFenNaZkl2ZlNTdnRBTHQ3eXA1X28zN3dOb0lNek5UMGwyRFguVGE5cmhMVwNzcGNCCmT5xf76ZO-1yiFSG3RyaXN0cmFtYmFsZHdpbjg4QGdtYWlsLmNvbVgEAAXhsQ~~) size was valued at USD 6.61 billion in 2022 and is projected to grow from USD 7.02 billion in 2023 to USD 11.26 billion in 2030, exhibiting a CAGR of 7.0% during the forecast period. The significant rise in the prevalence of this ailment around the world is one of the key factors that has a favorable effect on the global market. Age, expanding screen usage, poor diet, growing contact lens use, and even the growth of LASIK operations are contributing to the prevalence of cases. The growing eye industry is something investors can’t ignore much longer. The broader eyecare market was worth $6.6 billion in 2021 according to a[research report](~/AASl5QA~/RgRm3YPFP0SIaHR0cHM6Ly93d3cucmVwb3J0c2FuZGRhdGEuY29tL3JlcG9ydC1kZXRhaWwvZXllLWNhcmUtbWFya2V0P19reD1fLUhTcG8yeTlsRFdKZTVmSzZ4MzZXY3BlTWIwRXpzWmZJdmZTU3Z0QUx0N3lwNV9vMzd3Tm9JTXpOVDBsMkRYLlRhOXJoTFcDc3BjQgpk-cX--mTvtcohUht0cmlzdHJhbWJhbGR3aW44OEBnbWFpbC5jb21YBAAF4bE~) from Reports and Data. From this, the firm expects the market to grow at a 3.8% CAGR by 2030 and be worth an estimated $42.5 billion by the end of the forecast period! OKYO is concentrating on the development of its drug candidate OK-101 to treat ocular diseases, including: - Dry eye (DED) uveitis - Allergic conjunctivitis - Ocular pain This past May coverage on the company was initiated by Goldman Small Cap Research, who gave it a price target of $5.50! This price target is potentially nearly 200% upside from current levels! INVESTMENT HIGHLIGHTS FROM THE REPORT INCLUDE: - OKYO is poised to emerge as a key player in the Dry Eye Disease (DED) treatment market. Based on its preclinical studies, Goldman Small Cap Research believes OKYO could offer advantages over existing therapies, which are not viewed favorably by clinicians. These include fewer side effects, along with reduced inflammation and pain. - The ocular company industry and the DED sub- segment, are huge and growing at a rapid rate. The global DED market is expected to reach $6.54 billion in 2027, up from about $5.2 billion in 2019. - OKYO commenced a Phase II clinical trial with the objective of measuring safety and efficacy of OK-101 in DED patients, along with secondary endpoints such as ocular pain. A serious issue among a number of DED sufferers, there is no FDA approved product for neuropathic pain. - Top-line data from the trial is scheduled for release by year-end 2023 and serves as a major milestone for OKYO. Goldman Small Cap Research believes it is the catalyst for a re- valuation for the stock and for a mid-tier or top-tier firm to enter into a partnership with OKYO. - A 6–9-month price target for OKYO is $5.50. This target is based on the NPV of forecasted sales, a discounted price/sales multiple, discounted back five years at a reasonable discount rate. - The ocular treatment segment has garnered major attention. A flurry of M&A has occurred at high valuations, and OKYO’s peers also reflect these high valuation characteristics. Goldman Small Cap Research believes OKYO could emulate this trend in the future. You can read the full report [HERE.](~/AASl5QA~/RgRm3YPFP0SsaHR0cHM6Ly93d3cuZ29sZG1hbnJlc2VhcmNoLmNvbS8yMDIzMDUwOTEzNzgvT3Bwb3J0dW5pdHktUmVzZWFyY2gvb2t5by1pbm5vdmF0aXZlLWJpb3BoYXJtYS5odG1sP19reD1fLUhTcG8yeTlsRFdKZTVmSzZ4MzZXY3BlTWIwRXpzWmZJdmZTU3Z0QUx0N3lwNV9vMzd3Tm9JTXpOVDBsMkRYLlRhOXJoTFcDc3BjQgpk-cX--mTvtcohUht0cmlzdHJhbWJhbGR3aW44OEBnbWFpbC5jb21YBAAF4bE~) MORE ABOUT OK-101: OK-101 is a lipid-conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response. ChemR23 receptor on leukocytes targeted by OK-101 is also expressed on neurons and glial cells in the dorsal root ganglion and spinal cord. Such patients would benefit from a drug that comprises anti-inflammatory and neuropathic pain-reducing characteristics. The drug candidate has been shown to produce anti-inflammatory and neuropathic pain-reducing activities in mouse models of DED and corneal neuropathic pain, respectively, and is designed to combat washout through the inclusion of the lipid ‘anchor’ contained in the drug molecule to enhance the residence time of OK-101 within the ocular environment. As a Drug Candidate - Inflammation and pain are the most common symptoms of dry eye - OK-101 is a novel class of chemerin receptor agonist that produces an anti-inflammatory action and reduction in neuropathic pain - Inclusion of a lipid ‘anchor’ within the OK-101 drug molecule is designed to decrease washout due to tearing and blinking, and to enhance the ocular residence time of OK-101 Rapid Clinical Development - IND application cleared in Q4 2022 - Able to skip Phase 1 safety trial and go directly to Phase 2 safety and efficacy trial in dry eye disease patients - Phase 2 trial in dry eye disease patients started May 2023 - Topline data expected in Q4 2023 It wasn’t that long ago that the U.S. Food and Drug Administration (FDA) cleared OKYO’s Investigational New Drug (IND) to initiate a Phase 2, first-in-human, clinical study of OK-101 for the treatment of Dry Eye Disease (DED)! This trial is now underway and takes it closer and closer to a possible FDA approval! OK-101, the company’s game-changing drug candidate could put OKYO on the map. “One of the most exciting aspects of this innovative clinical program is that we can get a rapid and informative answer on both safety and efficacy of OK-101 by the end of the year,” said Gabriele Cerrone, Executive Chairman and Founder of OKYO Pharma. “Furthermore, positive results would allow us to expedite the program towards FDA approval by leveraging results from this phase 2 dry eye trial in lieu of one of the two required phase 3 trials needed to support U.S. marketing authorization. OKYO remains well-positioned as novel ophthalmic compounds in large markets represent promising acquisition targets as evidenced by the recent $5.9 billion Iveric deal.” Earlier this year one of the biggest headlines in biotech was the announcement from Astellas Pharma about agreeing to buy U.S. drugmaker Iveric Bio Inc for about [$5.9 billion](~/AASl5QA~/RgRm3YPFP0SkaHR0cHM6Ly93d3cucmV1dGVycy5jb20vbWFya2V0cy9kZWFscy9hc3RlbGxhcy1waGFybWEtYnV5cy1pdmVyaWMtYmlvLTU5LWJsbi0yMDIzLTA0LTMwLz9fa3g9Xy1IU3BvMnk5bERXSmU1Zks2eDM2V2NwZU1iMEV6c1pmSXZmU1N2dEFMdDd5cDVfbzM3d05vSU16TlQwbDJEWC5UYTlyaExXA3NwY0IKZPnF_vpk77XKIVIbdHJpc3RyYW1iYWxkd2luODhAZ21haWwuY29tWAQABeGx). That massive acquisition had closed in July. It is the biggest acquisition for Astellas yet, giving it access to a range of ophthalmology treatments…. The sheer magnitude of this deal has emphasized just how important the eye healthcare market is and the potential for OKYO! Very recently OKYO announced that the company has enrolled and randomized 90% of the patients in its 240-patient Phase 2 multi-center, double-masked, placebo-controlled clinical trial of topical ocular OK-101 to treat DED. About the Phase 2 Trial Design This phase 2, multi-center, randomized, double–blinded, placebo-controlled study is designed to enroll approximately 240 subjects with DED who are being randomly divided into 3 cohorts of 80 patients. Participants are being selected based on specific inclusion and exclusion criteria. The three cohorts include one cohort treated with placebo, a second cohort treated with 0.05% OK-101, and the third cohort receiving 0.1% OK-101. The drug and placebo, respectively, are being administered in both eyes twice daily for 12 weeks. The duration of a patient’s treatment is approximately 14 weeks, including a 2-week run-in period, to address the placebo effect, which is common for trials involving a pain component, followed by 12 weeks of treatment. The protocol for the study includes two prespecified primary endpoints and a number of secondary endpoints. Further details regarding the specifics of the trial are posted on the clinicaltrials.gov public website (clinicaltrials.gov Identifier: NCT05759208 or [. “The Phase 2 clinical trial is a crucial step in the development of OK-101, evaluating its safety, efficacy, and tolerability in a larger patient population. We sincerely appreciate the clinicians and staff that are contributing to the conduct of this trial and are extremely grateful to the patients that have chosen to participate. The Company remains laser-focused on completing the trial, which is managed by our clinical development partner Ora Inc. a world leader in dry eye clinical research, and is committed to establishing the potential of this drug to treat the many millions of people currently suffering from DED." - Raj Patil, Ph.D., CSO of OKYO Pharma The company has had many positive developments in recent months: In April: - OKYO announced the activation of the first clinical trial site in the U.S. for its phase 2, multi-center, randomized, double-blinded, placebo-controlled trial, evaluating the efficacy and safety of OK-101 ophthalmic solution in subjects with DED. In May: - OKYO announced that the first patient has been screened for its phase 2, multi-center, randomized, double–blinded, placebo-controlled trial, evaluating the efficacy and safety of OK-101 ophthalmic solution in subjects with DED. - OKYO announced that two presentations were to be given on OK-101 at the American Society of Cataract and Refractive Surgery (ASCRS 2023) in San Diego, CA, May 5-8, 2023. In June: - OKYO announced that patients were now being dosed in the randomized portion of the phase 2, multi-center, double-masked, placebo-controlled trial of topical ocular OK-101 to treat DED, following the two-week placebo run-in period intended to minimize the placebo effect. In July: - OKYO announced a new agreement with Tufts Medical Center to conduct a 40-patient open-label clinical trial evaluating the efficacy and safety of OK-101 in patients with neuropathic corneal pain (“NCP”). The Investigational New Drug (“IND”) application for NCP is planned to be filed in Q4 of 2023, with study enrollment planned to commence shortly after IND allowance by the FDA. In Summary… OKYO is an emerging player in eye treatment could be trading at a PREMIUM right now, as it leads the way in eye care advancements. If OKYO’s OK-101 phase 2 trial is successful, it may serve as one of two required phase 3 studies necessary to support FDA approval! OKYO’s immediate goal is to overcome the limitations of current dry eye treatments with the development of a first-in-class drug that combines both anti-inflammatory and pain-reducing activity. This would be a FIRST! Dry eye patients suffer from corneal neuropathic pain, making their condition more resistant to anti-inflammatory drugs. Currently, there is NO FDA-approved topical treatment for ocular pain. Top-line data from OKYO’s Phase 2 trial is anticipated before the year ends… keep an eye out for this!! Start your research right away! Copyright 2023 © SCDalerts.com is owned and operated by the owner of SCD Media LLC. Disclaimer and Privacy For more Information please contact info@smallcapsdaily.com This website provides information about the stock market and other investments. This website does not provide investment advice and should not be used as a replacement for investment advice from a qualified professional. This website is for informational purposes only. The Author of this website is not a registered investment advisor and does not offer investment advice. You, the reader, bear responsibility for your own investment decisions and should seek the advice of a qualified securities professional before making any investment. Nothing on this website should be considered personalized financial advice. Any investments recommended here in should be made only after consulting with your personal investment advisor and only after performing your own research and due diligence, including reviewing the prospectus or financial statements of the issuer of any security. SCD Media, its managers, its employees, affiliates, and assigns (collectively "The Company") do not make any guarantee or warranty about the advice provided on this website or what is otherwise advertised above. To the maximum extent permitted by law, the Company disclaims all liability in the event any information, commentary, analysis, opinions, advice and/or recommendations provided herein prove to be inaccurate, incomplete, or unreliable, or result in any investment or other losses. You received this message as part of your subscription to SCD Alerts. SCD Alerts is a financial news and information website. We do not directly sell any products or offer any personal financial advice, nor do we advocate the purchase or sale of any security or investment for any specific individual. We also do not make any guarantee or warranty about what is advertised above. If you have questions or concerns about a product you’ve seen in one of our emails, we encourage you to reach out to that company directly. Disclaimer – Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated, and edited by SCD Media. Any wording found in this e-mail or disclaimer referencing “I” or “we” or “our” or “SCD” refers to SCD Media. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are therefore unqualified to give investment recommendations. Companies with low prices per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service, you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website. We do not advise any reader to take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and its owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares, we will list the information relevant to the stock and the number of shares here. We do not own any shares in OKYO. We have been currently compensated up to Twenty Five Thousand Dollars Cash ($25,000) via bank wire transfer from a third-party IA Media, LLC for a 1 Day Marketing Program regarding OKYO with a start date of 9/08/2023. SCD’s business model is to receive financial compensation to promote public companies. This compensation is a major conflict of interest in our ability to be unbiased regarding our alerts. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non- compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, SCD often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice. Small Caps Daily 1334 Northampton St Easton, PA 18042 © 2023 | All rights reserved. [Unsubscribe](~/AASl5QA~/RgRm3YPFP0SpaHR0cHM6Ly9tYW5hZ2Uua21haWwtbGlzdHMuY29tL3N1YnNjcmlwdGlvbnMvdW5zdWJzY3JpYmU_YT1UYTlyaEwmYz0wMUdBUDRURE0xUkE3R1FXWDRXNUZONUpCViZrPTFhOTc5MjY1ZGNmNjg1M2Y1ZmJhOWM4OWMyYmYxYmMyJm09MDFIOVNEU1BSVzJGQUpHNVNRUlhEOEFaQUYmcj0zMjk1dnpMVFcDc3BjQgpk-cX--mTvtcohUht0cmlzdHJhbWJhbGR3aW44OEBnbWFpbC5jb21YBAAF4bE~). [Twitter] [Facebook] [Instagram]